As a response to Congress, the FDA's recent report highlighted the actions being considered to promote the possible regulatory pathways for CBD-infused items.
It is being noted that the FDA’s report indicated a shift in policy in regards to CBD-infused dietary supplements. In this concern, the FDA will examine the differences between full-spectrum and broad-spectrum CBD items in comparison with isolate CBD items. The obtained information will be mandatory for evaluating the regulatory status of such items.
The FDA also reassured about its safety concerns while using CBD items. The agency wants to make sure about CBD’s effects on children, elderly and women who are conceived. The important questions relating to CBD’s safe use include the effects of using CBD daily in different methods such as oral consumption, vaping and topical use and some other related questions.
The FDA reports also affirmed its regulation for CBD vape items and stated that such items cannot be marketed without FDA permission. However, most CBD-infused vape items do not contain tobacco or nicotine.
Further, the report stated that the agency is keenly monitoring the CBD market for identifying items that can be harmful to consumers. It includes products that are being labeled with unproven therapeutic claims or items that are being supplied by unreliable suppliers, which are not good for the public. Therefore, the report added that the FDA is assessing the issuance of a new enforcement policy that will bring more transparency.
Last but not least, the agency will be collaborating with state regulators and federal agencies to discuss and share information on CBD. To put it shortly, it is the first time when the FDA report showed clearance of the agency concerning CBD in food, beverages, and dietary supplements. The agency is looking forward to coming up with a feasible regulatory pathway for CBD dietary supplements.